Encapsulate

Encapsulate is a private, pre-revenue diagnostics company founded in 2021 and headquartered in San Diego, CA, USA. It has developed an automated 'tumor-on-a-chip' platform that creates microtumors from patient biopsies to functionally test drug responses, aiming to personalize cancer therapy selection. The company has secured significant non-dilutive grant funding from NASA and the NSF, closed an oversubscribed $1.8M seed round, and is actively engaged in research, including unique microgravity studies on the International Space Station. Its primary business model is providing diagnostic testing services to oncologists and collaborative R&D services to pharma.

Automated tumor-on-a-chip and metastasis-on-a-chip microfluidic systems that create 3D microtumors from patient biopsies for functional drug response testing.

Encapsulate competes in the functional precision oncology space with companies like SEngine Precision Medicine (PARIS test) and Kiyatec, which also use patient-derived 3D cultures for drug response profiling. It also faces indirect competition from dominant genomic profiling firms (e.g., Foundation Medicine, Guardant Health). Its differentiation lies in its automated, microfluidic platform aiming for a 7-day turnaround and its innovative NASA-backed microgravity metastasis research.